Merck's Keytruda Hits a Main Endpoint in Colorectal Cancer Study
April 02 2020 - 7:42AM
Dow Jones News
By Colin Kellaher
Merck & Co. on Thursday said its cancer drug Keytruda met
one of two primary endpoints in a Phase 3 study in a form of
colorectal cancer.
The Kenilworth, N.J., drug maker said Keytruda significantly
improved progression-free survival as first-line treatment in
patients with microsatellite instability-high or mismatch repair
deficient unresectable or metastatic colorectal cancer compared
with chemotherapy.
Merck said the study will continue without changes to evaluate
overall survival, the other dual primary endpoint, adding that
Keytruda's safety profile was consistent with previous studies,
with no new safety signals identified.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
April 02, 2020 07:27 ET (11:27 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Merck (NYSE:MRK)
Historical Stock Chart
From Apr 2024 to May 2024
Merck (NYSE:MRK)
Historical Stock Chart
From May 2023 to May 2024
